巨子生物三类械成功获批；泡泡玛特Q3业绩高增：新消费行业周报（2025.10.20-2025.10.24）-20251027

Investment Rating - The industry investment rating is "Positive" (maintained) [3] Core Insights - The successful approval of Class III medical devices by Juzi Biotech opens up growth opportunities in the medical beauty sector. The product, "Recombinant Type I α1 Collagen Lyophilized Fiber," is the first of its kind in China and is expected to enhance the company's product matrix and growth trajectory in the medical beauty segment [4] - Pop Mart's Q3 performance shows a significant revenue increase of 245-250% year-on-year, driven by the sustained influence of popular IPs. Revenue growth in China was 185-190%, with online channels growing by 300-305% [4] Summary by Sections Industry Performance - The new consumption sector showed varied performance, with the beauty care index down by 0.09%, the retail index up by 0.46%, and the social services index up by 2.60% during the week of October 20 to October 24, 2025 [7] Key Industry Data - In September, retail sales for clothing and textiles increased by 4.7% year-on-year, cosmetics by 8.6%, and gold and silver jewelry by 9.7%. However, beverage retail sales saw a decline of 0.8% [11] Investment Analysis Recommendations - The report suggests focusing on high-quality domestic brands in the beauty sector, such as Mao Ge Ping and Shumei Co. In the gold and jewelry sector, brands like Laopu Gold and Chaohongji are recommended. For trendy toys, companies with strong IP creation and operation experience, like Pop Mart, are highlighted. In the ready-to-drink tea sector, brands with strong market presence like Mixue Group and Guming are advised [18]